LearnICU is a comprehensive library housing thousands of online educational materials, many available only to SCCM members.
Search the library or explore resources sorted by Knowledge Line (Category) or Content Type.
LearnICU > SCCM Pod-440 Optimal Sedation in Patients Who Receive Neuromuscular Blocking Agent Infusions for Tre
SCCM Pod-440 Optimal Sedation in Patients Who Receive Neuromuscular Blocking Agent Infusions for Treatment of ARDS
Two previously published trials (ARDS et Curarisation Systematique [ACURASYS] and Reevaluation of Systemic Early Neuromuscular Blockade [ROSE]) presented equivocal evidence on the effect of neuromuscular blocking agent infusions in patients with acute respiratory distress syndrome. Host Kyle B. Enfield, MD, FCCM, is joined by Matthias Eikermann, MD, to discuss the different sedation regimens between these two trials as well as the different regimens within the ROSE trial between treatment and control groups. They will also discuss the hypothesis that the proportion of deeper sedation is a mediator of the effect of neuromuscular blocking agent infusions on mortality (Wongtangman K, et al. Crit Care Med. 2021;49:1137-1148; Jabaley C, Crit Care Med. 2021;49:1211-1213).
Dr. Eikermann is a professor of anesthesia at Harvard Medical School and an attending anesthesiologist and vice chair of faculty affairs in the Department of Anesthesia, Critical Care and Pain Medicine at Beth Israel Deaconess Medical Center. This podcast is sponsored by Sound Physicians.
Estimated Time: 23:44 min